Synthesis and Anticancer Properties of Methyl N1-(thien-4-yl)amidrazone- 3-carboxylates

Author(s): Ali M. Almansour, Jalal A. Zahra*, Salim S. Sabri, Mustafa M. El-Abadelah, Malik A. Zihlif, Mutasem O. Taha.

Journal Name: Letters in Drug Design & Discovery

Volume 15 , Issue 12 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: A variety of synthetic amidrazones are endowed with antitumor activity. Examples include N1-(thien-3-yl)amidrazone-2-carboxylates that exhibit high potency against breast cancer (MCF-7) and leukemia (K562) cell lines. These results prompted us to design and examine a new set of isomeric N1-(thienyl)amidrazone.

Methods: The synthesis of the targeted N1-(thien-4-yl)amidrazone-4-carboxylates 7a-n is achieved via interaction of the appropriate (N-substituted)piperazine with nitrile imine 1,3 dipole (generated in situ from the N1-(thien-4-yl)hydrazonoyl chloride precursor by the action of NEt3).

Results: Among the tested compounds 7a-n, the amidrazone (7m) incorporating N4-(pyridin-2- yl)piperazine moiety was the most active against leukemia (K562) with IC50 value of 1.02 μM. Docking studies showed that 7m binds with the oncogenic protein kinase Bcr-Abl. Noteworthy, compound 7m shows negligible cytotoxic effect on human normal fibroblast cells.

Conclusion: Compound 7m could probably act as a prospective lead structure for development of new synthetic N1-(thienyl)amidrazones against leukemia (K562).

Keywords: Methyl 4-aminothiophene-3-carboxylate, (Thien-4-yl)hydrazonoyl chloride, (Thien-4-yl)amidrazones, Antitumor activity, leukemia, cytotoxic effect.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 15
ISSUE: 12
Year: 2018
Page: [1268 - 1275]
Pages: 8
DOI: 10.2174/1570180815666180306152143
Price: $58

Article Metrics

PDF: 16
HTML: 1
PRC: 1